CytoPak GMP Human IL-15 Protein

No equivalent PG product available.
1/7
+4 View all
製品番号/仕様
価格
Availability
数量
CytoPak
GMP-L15H13GB02-50ug
Inquire
In Stock - Delivery in 2-3 business days
GMP lyophilized
GMP-L15H13-50ug
$855.00
In Stock - Delivery in 2-3 business days
GMP-L15H13-1mg (50ug X 20)
$7,325.00
In Stock - Delivery in 2-3 business days
GMP-L15H13-10mg (50ug X 200)
$51,275.00
CytoPak
GMP-L15H13GB01-10ug
$370.00
In Stock - Delivery in 2-3 business days
GMP-L15H13GB02
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
IL-15 PRODUCT SHOW

CytoPak GMP Human IL-15 Protein is packaged in sterile closed containers that can be readily incorporated into ex vivo clinical production processes. The bag utilizes medical grade multilayer film with two weldable options. The outlet weldable tube contains a proximal TPE section (1/8’’ ID x 1/4’’ OD) and a distal PVC section (3/32’’ ID x 5/32’’ OD). The liquid state and closed-system packaging of CytoPak GMP Human IL-15 Protein can be directly welded to GMP media bags resulting in safety and user-friendliness by bypassing the reconstitution step during manufacture.

GMP Platform Advantages
  • Quality Assurance: Global QMS with comprehensive and stringent QC release criteria.
  • End-to-End GMP Compliance: Full manufacturing and QC under a cGMP system.
  • Comprehensive Control of Adventitious Agents: Stringent biosafety from cell banks to final release.
  • Comprehensive Regulatory Support: Includes RSF and DMF to meet global requirements.
  • Resilient Supply Chain: Intelligent modular facilities ensure a stable global supply.
  • Professional Support: Extensive manufacturing and application expertise to accelerate development.
Source

CytoPak GMP Human IL-15 Protein (GMP-L15H13GB02) is expressed from E. coli cells. It contains AA Asn 49 - Ser 162 (Accession # P40933-1).

Molecular Characterization

This protein carries no "tag".

The protein has a calculated MW of 12.9 kDa. The protein migrates as 13 kDa±3 kDa under reducing (R) condition (SDS-PAGE).

N-terminal Sequence Analysis

Met-Asn-Trp-Val-Asn-Val-Ile-Ser-Asp-Leu-Lys-Lys-Ile-Glu-Asp
(Routinely tested)

Endotoxin

Less than 1.0 EU/mL, tested by the LAL method in compliance with USP <85> and Ph. Eur. 2.6.14.

Host Cell Protein

<0.5 ng/µg of protein tested by ELISA.

Host Cell DNA

<0.02 ng/μg of protein tested by qPCR.

Sterility

Sterility testing was performed using the membrane filtration method in compliance with USP <71> and Ph. Eur. 2.6.1.

Mycoplasma

Negative

Purity

>95% as determined by SDS-PAGE.

Formulation

Supplied as 0.2 μm filtered solution in PBS, rHSA, pH7.4.

Contact us for customized product form or formulation.

Shipping and Storage

This product is supplied and shipped on dry ice.

Upon receipt, store it immediately at -20°C or lower for long term storage.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • Can be stored up to 24 months at -20°C;
  • Can be stored up to 2 weeks at 2-8°C.

バックグランド

Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells; cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.